Written by the Nuvirox Research Team
Short answer: mouse studies are genuinely encouraging for cartilage protection, but a comprehensive review of 25 published human NR trials found few clinically relevant effects overall — and none specifically measured joint pain or osteoarthritis.
Key Points
- In mouse models, boosting NAD+ activity reduced cartilage cell death and slowed osteoarthritis-like joint damage.
- A related NAD+ precursor (NRH) reduced pain and disease progression after joint injury in mice.
- No published human trial has tested NAD+ precursors specifically for osteoarthritis, joint pain, or cartilage outcomes.
Why cartilage cells are especially NAD+-hungry
Cartilage is unusual tissue: it has no blood supply of its own, so the cells that maintain it (chondrocytes) rely heavily on efficient mitochondrial function to meet their energy needs in a low-oxygen environment. That makes them particularly sensitive to the kind of mitochondrial and oxidative stress that comes with declining NAD+. In osteoarthritis, this shows up as chondrocyte death and a breakdown in cartilage's ability to repair itself faster than it degrades.
Researchers investigating the mitochondrial unfolded protein response (UPRmt) — a stress-response system inside mitochondria — found that boosting this response with nicotinamide riboside significantly improved mitochondrial function and reduced chondrocyte death in models of osteoarthritis, while also reducing pain behavior and slowing disease progression in mice. A related, more bioavailable NAD+ precursor called dihydronicotinamide riboside (NRH) produced similar protective effects against post-traumatic osteoarthritis in animal models.
What the human evidence actually says
This is a case where the preclinical story is specific and mechanistically interesting, but the human trial record simply hasn't caught up. A rigorous review that critically assessed all 25 published human research articles on nicotinamide riboside supplementation — spanning cardiovascular, metabolic, muscle, and safety outcomes — concluded that oral NR supplementation has displayed few clinically relevant effects overall, and cautioned that the broader literature has a tendency to overstate the robustness of reported benefits [1]. Joint pain and osteoarthritis outcomes were not among the endpoints those 25 trials measured at all.
That's an important distinction: this isn't a case of human trials testing joint pain and finding no effect. It's a case of the relevant human trials not existing yet.
What NAD+ won't do
NAD+ precursors are not an established treatment for osteoarthritis or joint pain, and shouldn't replace evaluated approaches — appropriate exercise and physical therapy, weight management where relevant, anti-inflammatory strategies your doctor recommends, and for more advanced cases, options like injections or surgical consultation. If joint pain is new, worsening, or accompanied by swelling, warmth, or reduced range of motion, that warrants a medical evaluation rather than a supplement trial, since some causes of joint pain (inflammatory arthritis, infection, gout) need specific diagnosis and treatment.
A reasonable way to think about the evidence gap
NR does have a broader, separately-established safety profile from unrelated human trials — including an 8-week safety study and dozens of others — so there's no particular safety red flag here. The uncertainty is entirely about efficacy for this specific use, not safety. If you're already taking an NAD+ precursor for general cellular energy reasons and happen to have joint discomfort, there's a plausible (if unconfirmed) mechanism that might apply. But it would be inaccurate to start one specifically expecting a joint-pain benefit based on current evidence.
Frequently asked questions
Does NAD+ help with arthritis or joint pain?
There's no direct human evidence either way. Mouse studies show NAD+-boosting compounds protect cartilage cells and reduce pain behavior, but this hasn't been tested in people with osteoarthritis.
Is nicotinamide riboside safe to try for joint pain?
The general safety profile of NR from unrelated human trials is reassuring, but there's no evidence it's effective specifically for joint pain — so any benefit would be speculative, not established.
What actually has good evidence for osteoarthritis?
Structured exercise programs, physical therapy, weight management (if relevant), and — for more severe cases — medical or surgical options your doctor can discuss. These have real human trial support behind them.
Should I see a doctor about joint pain instead of trying supplements?
If pain is new, worsening, or comes with swelling, warmth, or reduced motion, yes — some causes need specific diagnosis (like inflammatory arthritis or infection) that a supplement can't address.
If bone health is also part of what you’re thinking about, our companion article on NAD+ and bone density covers the related skeletal aging research, and for the broader mitochondrial-aging picture, see mitochondria supplements for which ingredients actually have human evidence.
Are there any human trials currently underway for NAD+ and joint pain?
None have been identified in the current published or registered trial literature specifically targeting osteoarthritis or joint pain outcomes with NAD+ precursors — this remains an open research gap rather than a study in progress.
One more piece of the preclinical picture worth knowing: researchers have also tested a related but distinct NAD+ precursor called dihydronicotinamide riboside (NRH), which is more efficiently converted to NAD+ in some tissue models than standard NR. In mouse models of post-traumatic osteoarthritis — the kind that develops after a joint injury like an ACL tear — NRH significantly inhibited both disease development and the associated pain. This suggests researchers see enough promise in the underlying mechanism to keep testing different delivery forms of NAD+ precursors specifically for joint outcomes, even though none of that work has yet reached human trials.
It’s also worth noting that osteoarthritis trials generally require large sample sizes and long follow-up periods to detect meaningful differences in pain and function, since both fluctuate naturally and respond notably to placebo. That’s a real practical barrier to running this kind of trial, separate from any question about whether the underlying biology is promising — which may partly explain why, despite encouraging mouse data, no group has yet taken on a dedicated human osteoarthritis trial for NAD+ precursors. Until one does, the fair summary is "biologically plausible, clinically untested," which is a meaningfully different claim than "proven to help."
From Nuvirox
Why we formulated NAD+ Restore
If what you're dealing with sounds like it belongs in a doctor's office rather than a supplement aisle, please start there — a clinician can rule out the specific causes discussed above. For general cellular energy support, each serving of NAD+ Restore provides 500 mg of nicotinamide riboside chloride (NR), one of the two most-researched NAD+ precursors, within the dose range used in published human trials, alongside 150 mg trans-resveratrol and 50 mg quercetin (polyphenols studied alongside NAD+ pathways for cellular health support) and 10 mg of galactomannans from fenugreek to support absorption.
We back it with a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
Learn more about NAD+ Restore →The bottom line
The cartilage-protection story in mice is genuinely interesting mechanistic science, built around a specific, well-characterized stress-response pathway. But it hasn't been tested in humans with joint pain or osteoarthritis, and a comprehensive review of the existing human NR trial record found limited clinically relevant effects across the outcomes that have been studied. This is an evidence gap worth watching, not a supported benefit to expect today.
References
- Damgaard MV, Treebak JT. What is really known about the effects of nicotinamide riboside supplementation in humans. Sci Adv. 2023;9. doi:10.1126/sciadv.adi4862.
- McDermott MM, Martens CR, Domanchuk KJ, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun. 2024;15:5046. doi:10.1038/s41467-024-49092-5.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.